These can be reversed by inhibiting PAI-1 activity using small-molecule inhibitors [82,83,84,85] suggesting that the tPA/PAI-1 system is a potential therapeutic target for many pathological conditions, such as cardiovascular diseases, metabolic disorders, fibrosis, cancer, and inflammatory and infectious diseases (Table 1). This evidence concerns the gene SERPINE1 and metabolic disease.